Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
121,543,157
-
Total 13F shares
-
45,770,959
-
Share change
-
+17,019,628
-
Total reported value
-
$70,490,000
-
Price per share
-
$1.54
-
Number of holders
-
37
-
Value change
-
+$26,192,633
-
Number of buys
-
23
-
Number of sells
-
12
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q3 2022
As of 30 Sep 2022,
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,770,959 shares.
The largest 10 holders included
NEA Management Company, LLC, Fairmount Funds Management LLC, Rubric Capital Management LP, Frazier Life Sciences Management, L.P., VIKING GLOBAL INVESTORS LP, VR Adviser, LLC, MAI Capital Management, FMR LLC, VANGUARD GROUP INC, and Altium Capital Management LP.
This page lists
37
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.